Navigation Links
WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
Date:1/16/2008

SHANGHAI, China, Jan. 16 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), China's leading provider of pharmaceutical R&D outsourcing services is proud to announce today that its Chairman and Chief Executive Officer Dr. Ge Li is named as one of the 2007 China Top 10 Influential Entrepreneurs selected by Entrepreneur China edition.

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

The 2007 China Top 10 Influential Entrepreneurs selection, organized by Entrepreneur China edition, aims to honor Chinese entrepreneurs who have enabled enormous leaps for their enterprises and whose experiences have prompted profound changes in the Chinese society during the year of 2007. The selection of the winners is based on a comprehensive set of parameters to evaluate the entrepreneur's contribution to revenue growth, employment opportunities, industry impact, public influence and social recognition, capital market performance, wealth creation for employees, as well as social responsibilities. Seeking to exemplify China's most successful entrepreneurs and inspire the new generation to run their own businesses, the organizer selected China's ten most influential business luminaries from over 100 achieved entrepreneurs who brought their companies public in 2007.

Dr. Li has won the award because of his deep understanding of the global pharmaceutical R&D outsourcing market and the successful implementation of his visionary business model and strategy in China. "Under Dr. Li's leadership, WuXi PharmaTech is playing an increasingly important role in the global drug discovery and development industry. This eventually will positively impact China's pharmaceutical industry," according to Entrepreneur.

Founded in 2000, through seven years of rapid development, WuXi PharmaTech has gained trust and confidence from the world's leading pharmaceutical and biotechnol
'/>"/>

SOURCE WuXi PharmaTech
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. WuXi PharmaTech Schedules 2007 Second Quarter Earnings Release on Thursday, September 6, 2007
2. WuXi PharmaTech Announces Second Quarter 2007 Results
3. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
4. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
5. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
6. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
7. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
8. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
9. DuPont, Genencor International and Tate & Lyle Honored for Groundbreaking Work in Developing Bio-PDO(TM)
10. Aflac Honored with Corporate Citizenship Award
11. Dr. Dinesh Verma to be honored with Presidents Leadership Award at Edwin A. Stevens Society Gala

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)... November 5, 2009 Senomy...ng proprietary taste receptor-based technologies t...beverage, and ingredient supply industries, today ... results for the third quarter ended September 30,...uarter of 2009, compared to $4.0 million for the t...
(Date:11/5/2009)... Drug safety specialty firm BioSoteria announ...matics earned the Certified Professional in Learni...he American Society for Training and Development (...as more than fifteen years of medical communicatio...onsible for the development of the company,s onlin...
(Date:11/4/2009)... The Human Anthrax Vaccine Program must be st... feature film "A Call to Arms:2009 Edition&qu...Fatal Immunity: The Human Anthrax Vaccine Story&qu...nt danger of top secret government science turned ...ountability to its victims. It is available for w...
(Date:11/4/2009)...lif., Nov. 4 Onyx Pharma...hat it will present at the Credit Suisse 18th Annu..., at 9:30 a.m. Mountain Time (8:30 a.m. Pacific Ti... of the presentation on our website at: http://w..., It is recommended that listeners log on 15 minu...
Breaking Biology Technology:SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 2BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 3BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 4Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 2Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 3Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 4Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 5Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 6Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 7
...nc. (Nasdaq: DCTH ), a medical technology compa...rfusion ("PHP") System for the treatment of cancer...ty percent (46 of 92) of patients have been enroll...atic cutaneous and ocular melanoma to the liver. ...ial continue to evaluate and enroll patients and t...
.../ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ON...eeded the primary statistical endpoint in its mult...travenous administration of REOLYSIN(R) in patient...the lung. , "The proportion of patients on study...responses is highly encouraging," said Dr. Frank G...
... announced today,that it has agreed with Pfizer to...edients (API) site in Ireland. This site manufactu...l ingredient. , The site has had a number of..., then Hickson & Welch, Warner Lambert, Pfizer...s invested several hundred million dollars in,plan...
Other Biology Technology:Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 2Enrollment in Delcath's Pivotal Phase III Metastatic Melanoma Clinical Trial Reaches Halfway Point 3Oncolytics Biotech Inc.'s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study 2Oncolytics Biotech Inc.'s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study 3Oncolytics Biotech Inc.'s REOLYSIN(R) Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study 4Hovione Buys Pfizer's Loughbeg API Facility 2Hovione Buys Pfizer's Loughbeg API Facility 3
(Date:11/6/2009)...TROIT, Nov. 6 Auburn Hills, MI-bas... will be installing its locker system and patent-p...at the U.S. Department of Health and Human Service...thesda, MD. The locker system will support the NI...otecting our nation,s medical research agency. Th...
(Date:11/4/2009)...ELPHIA Although scientists are reluctant to offic...hod, evidence continues to grow about its protecti...shed in Cancer Prevention Research , a journal of...ch suggests some reduction in oral cancer. , Va...icine in the Department of Thoracic/Head and Neck ...
(Date:11/4/2009)...ngapore laboratory that deciphered the DNA codes, ...elephant shark, has joined The Genome 10K Project,...pository of DNA sequences on 10,000 species of ani... that currently can not be achieved. , Participa...er published in the Nov. 5, 2009 issue of the Jou...
Breaking Biology News(10 mins):Does green tea prevent cancer? Evidence continues to brew, but questions remain 2Singapore scientists join international study of 10,000 vertebrates' genomes 2Adam 26 Eves Great American Sex Survey Asks How Was YOUR First Time 3F 57838 1Adam 26 Eves Great American Sex Survey Asks How Was YOUR First Time 3F 57838 2Veterans Healing Initiative Formed to Help Meet Burgeoning Addiction and Mental Health Issues of Returning U S Veterans 57835 1Veterans Healing Initiative Formed to Help Meet Burgeoning Addiction and Mental Health Issues of Returning U S Veterans 57835 2Perrigo Company To Host Investor Day 57833 1
...xpected to exacerbate drought events throughout th...tion and failure of drought-sensitive crops. In a... in severity and length, making it difficult for p...dern varieties of potatoes are considered to be dr...on in the cold, dry Andean Altiplano gave rise to ...
...toes can be up to 1000 times larger than their wil..., domesticated food plants have larger fruits, hea...he characteristics that early hunter-gatherers cho...omatoes have been bred for shape, texture, flavor,...been difficult to study these traits in tomatoes, ...
...vailable in French and Spanish . , Montreal, ...re joining forces to protect and conserve the Mona...America,s shared environment. , Although the mona...r of extinction, its unique multigenerational migr...ngered biological phenomenon due to threats to the...
Other Biology News:Drought tolerance in potatoes 2Drought tolerance in potatoes 3Evolution of fruit size in tomato 2Evolution of fruit size in tomato 3Continental plan to protect the monarch's migratory journey 2
Rabbit Anti-KIAA1276 Polyclonal Antibody, Unconjugated from Abcam
Mouse Anti-Cytokeratin 5 / 14 Monoclonal Antibody, Unconjugated, Clone LH8 from Abcam
Rabbit Anti-IL-23 P19 Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-Human C1QC Polyclonal Antibody, Unconjugated from Atlas Antibodies
Biology Products: